CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

They’re at the center of a legal battle with the makers of specialized formulas for preterm infants — north suburban-based Abbott Laboratories ... the U.S. Food and Drug Administration ...

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value ... In June 2024, the FDA approved Abbott's two new over-the-counter continuous glucose monitoring (CGM) systems ...

As Abbott Laboratories prepares to build a plant and bring 450 jobs to Bowling Green, company officials asked for permission to have more fencing and less greenery than required by city zoning. On ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant ... could result in the product being spoiled. The FDA announced on Wednesday their continued efforts ...

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:ABT), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

Abbott Laboratories ABT will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

Nov 1 (Reuters) - Abbott Laboratories (ABT.N), opens new tab shares ... Editing by Shilpi Majumdar Healthcare & Pharmaceuticalscategory US FDA lifts clinical hold on Novavax's combo COVID-flu ...